- Conditions
- Obesity
- Interventions
- Exercise, Diet
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–56
of 56
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neuroblastoma
- Interventions
- Protracted Oral Etoposide, Doxorubicin, IV Bolus Etoposide, Cisplatin, Cyclophosphamide, Mesna, Hematopoietic Factor, Primary tumor resection
- Drug · Procedure
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy
- Interventions
- Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T
- Other · Drug
- Lead sponsor
- AvenCell Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Evanston, Illinois • Providence, Rhode Island + 2 more
- Conditions
- Solid Tumours
- Interventions
- SB-715992, carboplatin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Plasma Cell Disorder
- Interventions
- 75gm HDAA, 100gm HDAA, 125gm HDAA
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Systemic Lupus Erythematosus, Systemic Sclerosis
- Interventions
- Nonmyeloablative allogeneic stem cell transplant
- Procedure
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2015
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Major Depressive Disorder
- Interventions
- Pathway Platform mobile app
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Oak Lawn, Illinois
- Conditions
- 1 Fluid Management
- Interventions
- Deltex CardioQ Probe
- Device
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Stony Brook, New York